Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(01): 4-11
DOI: 10.1055/s-0042-111684
Article
© Georg Thieme Verlag KG Stuttgart · New York

Acute Reduction of Incretin Effect and Glucose Intolerance in Rats by Single Intragastric Administration of 3-deoxyglucosone

Fei Wang   *
1   Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, P. R. China
,
Liang Zhou   *
1   Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, P. R. China
,
Xiudao Song
1   Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, P. R. China
,
Guoqiang Liang
1   Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, P. R. China
,
Heng Xu
1   Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, P. R. China
,
Lurong Zhang
1   Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, P. R. China
,
Guorong Jiang
1   Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, P. R. China
› Author Affiliations
Further Information

Publication History

received 26 June 2016
revised 26 June 2016

accepted 05 July 2016

Publication Date:
22 September 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Secretion of glucagon-like peptide-1 has been suggested to be impaired in T2DM and in conditions associated with hyperglycemia. 3-Deoxyglucosone, a dietary composition, has been suggested as an independent factor for the development of prediabetes. A-pathophysiological very high condition of 3DG concentrations administered i. v. induced acute glucose intolerance in rats. In this study, to examine the acute effects of single intragastric administration of 3DG at dose of potentially single-meal intake on plasma glucose, insulin, glucagon, total GLP-1 and total GIP levels in response to a glucose load, OGTT was performed immediately in normal Kunming mice or Sprague-Dawleys rats after 3DG administration. GLP-1 secretion, intracellular cAMP levels and 2-NBDG uptake were examined in STC-1 cells exposured to 3DG. In rats, 20 mg/kg 3DG i.g. (3DG-20 i.g.) impaired glucose tolerance (P<0.05) with increased AUC (1 070±105.2 vs. 918.0±91.20, P<0.05). The mice treated with 3DG-20 i.g. exhibited a similar effect, independent of the effect of plasma 3DG concentration. 3DG-20 i.g. treatment reduced plasma insulin concentrations with decreased AUC (3 552±300.2 vs. 4 715±420.5, P<0.05) in rats whereas plasma glucagon levels were not significantly different. These changes occurred in conjunction with decreased plasma GLP-1 and GIP levels (P<0.05). Furthermore, non-cytotoxic 3DG concentrations directly reduced GLP-1 secretion in STC-1, at least in part, by decreasing intracellular cAMP level and glucose uptake. We demonstrated for the first time that single intragastric administration of 3DG resulted in acute reduction of incretin effect and glucose intolerance, which was associated with a decrease in the biological function of GLP-1 by decreasing GLP-1 secretion.

Key Words

3-deoxyglucosone - acute glucose intolerance - acute reduction of incretin effect - prediabetes

* These authors contributed equally.


 

  • References

  • 1 World Health Organization, World Health Organization . Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization; 2006: 1-50
    Google Scholar
  • 2 American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37 (Suppl. 01) S81-S90
    CrossrefPubMedGoogle Scholar
  • 3 Tabák AG, Herder C, Rathmann W et al. Prediabetes: a high-risk state for diabetes development. The Lancet 2012; 379: 2279-2290
    CrossrefPubMedGoogle Scholar
  • 4 Cowie CC, Rust KF, Ford ES et al. Full accounting of diabetes and pre-diabetes in the U. S. population in 1988–1994 and 2005–2006. Diabetes Care 2009; 32: 287-294
    CrossrefPubMedGoogle Scholar
  • 5 Yang W, Lu J, Weng J et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-1101
    CrossrefPubMedGoogle Scholar
  • 6 Hu FB, Van Dam RM, Liu S. Diet and risk of type II diabetes: the role of types of fat and carbohydrate. Diabetologia 2001; 44: 805-817
    CrossrefPubMedGoogle Scholar
  • 7 Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344: 109-116
    CrossrefPubMedGoogle Scholar
  • 8 Kroh LW. Caramelisation in food and beverages. Food Chem 1994; 51: 373-379
    CrossrefPubMedGoogle Scholar
  • 9 Degen J, Hellwig M, Henle T. 1, 2-Dicarbonyl compounds in commonly consumed foods. J Agric Food Chem 2012; 60: 7071-7079
    CrossrefPubMedGoogle Scholar
  • 10 Niwa T. 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl 1999; 731: 23-36
    CrossrefPubMedGoogle Scholar
  • 11 Sakiyama H, Takahashi M, Yamamoto T et al. The internalization and metabolism of 3-deoxyglucosone in human umbilical vein endothelial cells. J Biochem 2006; 139: 245-253
    CrossrefPubMedGoogle Scholar
  • 12 Liang G, Wang F, Song X et al. 3-Deoxyglucosone induces insulin resistance by impairing insulin signaling in HepG2 cells. Mol Med Rep 2016; 13: 4506-4512
    CrossrefPubMedGoogle Scholar
  • 13 Hamada Y, Nakamura J, Fujisawa H et al. Effects of glycemic control on plasma 3-deoxyglucosone levels in NIDDM patients. Diabetes Care 1997; 20: 1466-1469
    CrossrefPubMedGoogle Scholar
  • 14 Beisswenger PJ, Howell SK, O’Dell RM et al. Alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001; 24: 726-732
    CrossrefPubMedGoogle Scholar
  • 15 Lal S, Kappler F, Walker M et al. Quantitation of 3-deoxyglucosone levels in human plasma. Arch Biochem Biophys 1997; 342: 254-260
    CrossrefPubMedGoogle Scholar
  • 16 Eriksson UJ, Wentzel P, Minhas HS et al. Teratogenicity of 3-deoxyglucosone and diabetic embryopathy. Diabetes 1998; 47: 1960-1966
    CrossrefPubMedGoogle Scholar
  • 17 Kusunoki H, Miyata S, Ohara T et al. Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 2003; 26: 1889-1894
    CrossrefPubMedGoogle Scholar
  • 18 Jiang G, Zhang L, Ji Q et al. Accumulation of plasma 3-deoxyglucosone impaired glucose regulation in Chinese seniors: implication for senile diabetes?. Diabetes Metab Syndr 2012; 6: 140-145
    CrossrefPubMedGoogle Scholar
  • 19 Liang G, Song X, Xu H et al. 3-Deoxyglucosone induced acute glucose intolerance in Sprague-Dawley rats: involvement of insulin resistance and impaired β-cell function. Exp Clin Endocrinol Diabetes 2016; DOI: 10.1055/s-0035-1565193. [Epub ahead of print]
    PubMedGoogle Scholar
  • 20 Wang Q, Jiang Gr, Zhang Lr. Effects of 3-deoxyglucosone on blood glucose of normal mice. Chinese Journal of Diabetes 2010; 18: 220-222
    PubMedGoogle Scholar
  • 21 Kato H, van Chuyen N, Shinoda T et al. Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. Biochim Biophys Acta 1990; 1035: 71-76
    CrossrefPubMedGoogle Scholar
  • 22 Poulsen MW, Bak MJ, Andersen JM et al. Effect of dietary advanced glycation end products on postprandial appetite, inflammation, and endothelial activation in healthy overweight individuals. Eur J Nutr 2014; 53: 661-672
    CrossrefPubMedGoogle Scholar
  • 23 Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157
    CrossrefPubMedGoogle Scholar
  • 24 Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Invest 2013; 4: 108-130
    CrossrefPubMedGoogle Scholar
  • 25 Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 2005; 128: 125-134
    CrossrefPubMedGoogle Scholar
  • 26 Nauck M, Stöckmann F, Ebert R et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52
    CrossrefPubMedGoogle Scholar
  • 27 Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015; 95: 513-548
    CrossrefPubMedGoogle Scholar
  • 28 Yabe D, Kuroe A, Lee S et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig 2010; 1: 56-59
    CrossrefPubMedGoogle Scholar
  • 29 Legakis IN, Tzioras C, Phenekos C. Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. Diabetes Care 2003; 26: 252
    CrossrefPubMedGoogle Scholar
  • 30 Zhang F, Tang X, Cao H et al. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci 2012; 9: 574-581
    CrossrefPubMedGoogle Scholar
  • 31 Vilsbøll T, Krarup T, Deacon CF et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-613
    CrossrefPubMedGoogle Scholar
  • 32 Cani PD, Holst JJ, Drucker DJ et al. GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol 2007; 276: 18-23
    CrossrefPubMedGoogle Scholar
  • 33 Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism 2013; 17: 819-837
    CrossrefPubMedGoogle Scholar
  • 34 Kjems LL, Volund A, Madsbad S. The effect of exogenous GLP-1 on the glucose mediated insulin secretion: A dose-response study in patients with Type 2 diabetes mellitus and control subjects (Abstract). Diabetologia 1999; 142: A39
    PubMedGoogle Scholar
  • 35 Nauck MA, Heimesaat MM, Orskov C et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307
    CrossrefPubMedGoogle Scholar
  • 36 Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999; 140: 1687-1694
    CrossrefPubMedGoogle Scholar
  • 37 Reimann F, Ward PS, Gribble FM. Signaling mechanisms underlying the release of glucagon-like peptide 1. Diabetes 2006; 55: S78-S85
    CrossrefPubMedGoogle Scholar
  • 38 Schuit FC, Huypens P, Heimberg H et al. Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes 2001; 50: 1-11
    Google Scholar
  • 39 Simpson AK, Ward PS, Wong KY et al. Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia 2007; 50: 2181-2189
    CrossrefPubMedGoogle Scholar
  • 40 Szasza kM, Christian F, Rosenthal W et al. Compartmentalized cAMP signalling in regulated exocytic processes in non-neuronal cells. Cell Signal 2008; 20: 590-601
    CrossrefPubMedGoogle Scholar
  • 41 Jang HJ, Kokrashvili Z, Theodorakis MJ et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A 2007; 104: 15069-15074
    CrossrefPubMedGoogle Scholar
  • 42 Margolskee RF, Dyer J, Kokrashvili Z et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci USA 2007; 104: 15075-15080
    CrossrefPubMedGoogle Scholar